Correlation Between of PET/CT and Molecular Subtypes and in Patients with Metastatic Breast Cancer.

Document Type : Original Article

Authors

1 Oncology and Nuclear Medicine Department, Cairo University, Egypt.

2 Maadi Armed Force Hospital. Egypt.

Abstract

FDG PET/CT whole-body imaging has higher sensitivity, specificity and accuracy as compared to CT in detection of metastatic spread and follows up after treatment. The aim of this study: to assess of the impact of PET/CT in patients with metastatic breast cancer and monitoring the therapy response in relation to different molecular subtypes. Material and Methods: The study included 40 patients classified into 4 molecular subtypes; Luminal A like subtype (13 patients), Luminal B+ subtype (15 patients), Luminal B- subtype (4 patients) and Basal like subtype (8 patients). All patients with possible metastatic breast cancer performed PET-CT before treatment, while 34 patients perform PET-CT after the end oftherapy. Results: on lesion based analysis the total numbers of metastatic lesions in CT and bone scan were 120 lesions (49 in LNs, 24 in lung, 8 in liver; while 39 in bone). Metastatic lesions in PET/CT were 76 lesions (46 in LNs, 22 in lung and 8 in liver and 22 in bone). During follow up after therapy, the majority of luminal A group showed complete response to therapy during follow up PET/CT scan. Also, luminal B+ subgroup showed partial response. While most of basal-like subgroup showed progressive disease. Conclusion: PET/CT can detect metastatic spread in breast cancer and monitor therapy response in relation to different molecular subtypes. The mean SUV max showed relation to the different molecular subtypes.

Keywords

Files

Share

How to cite

Statistics